Live Breaking News & Updates on Therapeutix Company Profile
Stay updated with breaking news from Therapeutix company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ocular Therapeutix (NASDAQ:OCUL – Get Rating) had its price target dropped by research analysts at Piper Sandler from $16.00 to $10.00 in a report released on Friday, The Fly reports. Piper Sandler’s target price would indicate a potential upside of 213.48% from the company’s previous close. Other equities analysts have also issued research reports about […] ....
Ocular Therapeutix (NASDAQ:OCUL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using […] ....
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Rating) has received a consensus rating of “Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have given a buy recommendation and one has assigned a […] ....
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Rating) was the target of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 4,670,000 shares, an increase of 20.4% from the February 13th total of 3,880,000 shares. Based on an average daily volume of 664,700 shares, the […] ....